Advances and considerations in AD tau-targeted immunotherapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towards the required role of tau in AD etiology. Importantly, a large number of studies investigate and characterize the plethora of pathological forms of tau protein involved in disease onset and propagation. Immunotherapy is one of the most clinical approaches anticipated to make a difference in the field of AD therapeutics. Tau -targeted immunotherapy is the new direction after the failure of amyloid beta (Aß)-targeted immunotherapy and the growing number of studies that highlight the Aß-independent disease process. It is now well established that immunotherapy alone will most likely be insufficient as a monotherapy. Therefore, this review discusses updates on tau-targeted immunotherapy studies, AD-relevant tau species, updates on promising biomarkers and a prospect on combination therapies to surround the disease propagation in an efficient and timely manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“However, the only problem with this biomarker is that it is not disease specific, rather it is neurodegeneration specific (Khalil et al., 2018).”
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Some studies suggest that Aß malfunction lies upstream of tau malfunction and triggers tau pathology (Bloom, 2014; Hurtado et al., 2010; Lewis et al., 2001; Götz et al., 2001).”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Some studies suggest that Aß malfunction lies upstream of tau malfunction and triggers tau pathology (Bloom, 2014; Hurtado et al., 2010; Lewis et al., 2001; Götz et al., 2001).”
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 2×
“Aß and tau, primarily the oligomeric species of each, have been shown to be neurotoxic both extracellularly and intracellularly (Frost et al., 2009; SebastiánSerrano et al., 2018).”
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“, 2018), APOE4 carriers (Safieh et al., 2019; Shi et al., 2017) , and patients with TBI history (Gerson et al.”
BackgroundMethodCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“To obtain more accurate biomarkers for AD, the field has turned to combining tau and Aß measures and calculating the ratio of tau to Aß42 in the CSF as a measure of AD pathology (Chiaravalloti et al., 2018; Fagan et al., 2007).”
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836 · cited 2×
“, 2007) and in intracellular transport (Rodrigues et al., 2012; Kametani and Hasegawa, 2018) In addition, APP fragments have been shown to disrupt synaptic plasticity and cellular metabolism, and accumulate in dystrophic neurites (Kametani and Hasegawa, 2018) in both sporadic and familial AD.”
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · cited 2×
“Targeting Aß was shown to be ineffective in early intervention studies in patients with mild cognitive impairment (MCI) and prodromal Alzheimer’s disease (AD) (Cummings et al., 2018).”
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
B-cell responses to vaccination at the extremes of age
Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628 · cited 1×
“In addition, the tracer F18-AV1451 successfully discriminated tau pathology levels between normal and MCI patients, as well as between MCI and AD patients (Brier et al., 2016; Leuzy et al., 2019; Passamonti et al., 2017).”
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · cited 2×
“Soluble tau oligomers have been shown to increase in the brain long before symptoms and pathology start (Sato et al., 2018; Maeda et al., 2006; Lasagna-Reeves et al., 2012) and correlate with the start of neuronal death and progression during disease stages more than larger or insoluble tau…”
BackgroundYanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · cited 1×
“However, very few studies showed an effect with targeting phospho-tau on cognitive decline (Yanamandra et al., 2013).”
Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., Steinberg, J. I., Margittai, M., Kayed, R., Zurzolo, C., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394528 · Cited by 537
Self-citationIdentification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527
Self-citationAsuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 1×
“However, there are only a few studies that showed behavioral cognitive benefit along the tau reduction (Asuni et al., 2007; Asuni et al., 2007; Troquier et al., 2012).”
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502 · cited 2×
“In a recent longitudinal study on old non-demented patients in Germany, FABP3 and neurogranin along with the basic AD biomarkers (p-tau, t-tau, and Aß) were measured in a cohort of cognitively healthy elderly (60–80 years old) (Höglund et al., 2017; Mattsson et al., 2016).”
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445
Phosphorylation of different tau sites during progression of Alzheimer’s disease
Neddens, J., Temmel, M., Flunkert, S., Kerschbaumer, B., Hoeller, C., Loeffler, T., Niederkofler, V., Daum, G., Attems, J., & Hutter-Paier, B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0557-6 · Cited by 384 · cited 3×
“Also, keeping in mind that different tau epitopes get hyperphosphorylated along the disease spectrum (Neddens et al., 2018).”
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Initiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314 · cited 1×
“spread of pathology and neurodegeneration (Guerrero-Muñoz et al., 2015; Shafiei et al., 2017; Fá et al., 2016).”
Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease
Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., & Takashima, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.11.009 · Cited by 301 · cited 1×
“Soluble tau oligomers have been shown to increase in the brain long before symptoms and pathology start (Sato et al., 2018; Maeda et al., 2006; Lasagna-Reeves et al., 2012) and correlate with the start of neuronal death and progression during disease stages more than larger or insoluble tau aggregates.”
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
Kaufman, S. K., Del Tredici, K., Thomas, T. L., Braak, H., & Diamond, M. I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1855-6 · Cited by 259 · cited 1×
“In turn, misfolded soluble tau spreads from cell-to-cell in a neuronal network dependent pattern starting in the entorhinal cortex, going through the hippocampus and reaching the isocortex (Kaufman et al., 2018; Neddens et al., 2018).”
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004667 · Cited by 245 · cited 1×
“It correlates well with CSF biomarkers and was recently found to predict onset of neurodegeneration in familial AD (Weston et al., 2017).”
BackgroundThe role of TREM2 in Alzheimer's disease and other neurodegenerative disorders
Carmona, S., Zahs, K., Wu, E., Dakin, K., Bras, J., & Guerreiro, R. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30232-1 · Cited by 244 · cited 1×
“Overall, PET imaging could be highly utilized in combination with CSF and blood biomarkers in clinical studies in smaller and specific populations like those with TREM2 variants (Gratuze et al., 2018; Carmona et al., 2018), APOE4 carriers (Safieh et al.”
Extracellular tau is toxic to neuronal cells
Gómez-Ramos, A., Díaz-Hernández, M., Cuadros, R., Hernández, F., & Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.078 · Cited by 241 · cited 1×
“Extracellular tau is known to exert cellular toxicity via mechanisms separate from those of intracellular tau by interacting with muscarinic cellular receptors or disrupting the cellular membrane (Gómez-Ramos et al., 2006; Yamada and Hamaguchi, 2018).”
Luna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., & Mena, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12410 · Cited by 233
Hurtado, D. E., Molina-Porcel, L., Iba, M., Aboagye, A. K., Paul, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100346 · Cited by 222 · cited 1×
“Some studies suggest that Aß malfunction lies upstream of tau malfunction and triggers tau pathology (Bloom, 2014; Hurtado et al., 2010; Lewis et al., 2001; Götz et al., 2001).”
BackgroundAmyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
Franz, G., Beer, R., Kampfl, A., Engelhardt, K., Schmutzhard, E., Ulmer, H., & Deisenhammer, F. (2003) · Neurology · doi:10.1212/01.wnl.0000063313.57292.00 · Cited by 217
Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation
McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201
Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · cited 1×
“These antibodies were shown to internalize into the neurons via clathrin mediated endocytosis which is a very promising step towards future immunotherapy clinical trials (Congdon et al., 2013; Gu et al., 2013; Krishnaswamy et al., 2014).”
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · cited 1×
“However, there are only a few studies that showed behavioral cognitive benefit along the tau reduction (Asuni et al., 2007; Asuni et al., 2007; Troquier et al., 2012).”
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · cited 3×
“, 2013), most antibodies are too bulky to enter the neuron for intracellular-tau clearance (Nisbet et al., 2017; Wu et al., 2018).”
BackgroundAnti‐tau antibody reduces insoluble tau and decreases brain atrophy
Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185
Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178 · cited 2×
“Therefore, the general conclusion was that Aß accumulation is irrelevant to neurodegeneration and might be just a consequence of the disease process (Panza et al., 2019).”
BackgroundTau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168 · cited 1×
“spread of pathology and neurodegeneration (Guerrero-Muñoz et al., 2015; Shafiei et al., 2017; Fá et al., 2016).”
The role of extracellular Tau in the spreading of neurofibrillary pathology
Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161
Review: Tau in biofluids – relation to pathology, imaging and clinical features
Zetterberg, H. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12378 · Cited by 157 · cited 1×
“The blood levels of t-tau are still controversial in terms of predictability of tau pathology and neurodegeneration in the brain, however, t-tau and p-tau are considered better blood biomarkers for AD, and the conversion from MCI to AD (Mielke et al., 2017; Zetterberg, 2017).”
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156 · cited 1×
“However, targeting Aß by immunotherapy did not lead to a decrease in tau pathology nor slowed down cognitive decline in clinical trials (Panza et al., 2019; Medina, 2018).”
Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4989-14.2015 · Cited by 149 · cited 1×
“TOMA1 is one of the few antibodies that showed tau oligomers depletion from the brain and an increase of oligomers in the CSF accompanied with cognitive improvement (Castillo-Carranza et al., 2015; Kolarova et al., 2016; Sengupta et al., 2017) (Fig.”
Self-citationNovak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147
Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144 · cited 1×
“PHF1 was tested in P301S, P301L, htau/PS1 and rTg4510 mouse models (Liu et al., 2016; Boutajangout et al., 2010; Chai et al., 2011; d’Abramo et al., 2013; Shahpasand et al., 2018).”
The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology
Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120
Distinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · cited 1×
“, 2017), and clearing the antibody-tau complex either to be degraded by microglia (Funk et al., 2015) or to be released to the periphery (blood) (Jadhav et al.”
Different tau species lead to heterogeneous tau pathology propagation and misfolding
Dujardin, S., Bégard, S., Caillierez, R., Lachaud, C., Carrier, S., Lieger, S., Gonzalez, J. A., Deramecourt, V., Déglon, N., Maurage, C.-A., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0637-7 · Cited by 109 · cited 1×
“It was recently shown that the exposure of an aggregation-prone domain due to misfolding renders tau conformations seed competent (Dujardin et al., 2018; Mirbaha et al., 2018) However, what renders a tau conformation toxic is still undetermined, aside from the loss of normal function.”
Gerson, J., Castillo-Carranza, D. L., Sengupta, U., Bodani, R., Prough, D. S., DeWitt, D. S., Hawkins, B. E., & Kayed, R. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4262 · Cited by 94 · cited 1×
“, 2017) , and patients with TBI history (Gerson et al., 2016).”
Self-citationTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87 · cited 2×
“This produces a lot of variability due to the variable levels of functionality and immunogenicity of the patients’ immune systems in a clinical trial, and therefore produce unreliable results (Novak et al., 2018a) (Fig.”
BackgroundTau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77 · cited 3×
“forms of pathological tau, like tau oligomers, come into the picture due to their higher toxicity and early on detection in the disease process (Dorey et al., 2015; Sengupta et al., 2017).”
Self-citationSigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · cited 1×
“…immunization in animal models have shown to be effective in reducing soluble and insoluble tau aggregates’ levels, as well as those of hyperphosphorylated tau that are believed to drive neurodegeneration and NFTs load (Sigurdsson, 2016; Sigurdsson, 2018; Theunis et al., 2013; Theunis et al., 2017).”
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
Self-citationNPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Cited by
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Zetterberg, H., & Bendlin, B. B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 377
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“Subsequently, numerous papers have reported effective targeting of multiple tau epitopes, including the amino terminus, the mid-domain, the microtubule-binding region, misfolded tau, p-tau202, p-tau231, p-tau396/404, p-tau409, p-tau413, p-tau422 and oligomeric tau species 57,165–172 .”
BackgroundGSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“The potential therapeutic actions of these antibodies have been tested in in vivo preclinical mouse models showing to reduce tau pathology and functional deficits (reviewed in [201]).”
BackgroundSengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
Self-citation
Metadata
- Authors
- Bittar, A., Bhatt, N., & Kayed, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 134
- Pages
- 104707
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2995934239
- Cited by
- 104
- References
- 63
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.